We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Neurocrine (NBIX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Wall Street analysts expect Neurocrine Biosciences (NBIX - Free Report) to post quarterly earnings of $2.26 per share in its upcoming report, which indicates a year-over-year increase of 113.2%. Revenues are expected to be $901.54 million, up 31.1% from the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Neurocrine metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Revenues- Product sales, net' will likely reach $881.08 million. The estimate indicates a year-over-year change of +29.2%.
Based on the collective assessment of analysts, 'Revenues- Collaboration revenue' should arrive at $6.02 million. The estimate points to a change of +9.4% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Product sales, net- INGREZZA' will reach $628.59 million. The estimate indicates a change of +0.7% from the prior-year quarter.
Over the past month, Neurocrine shares have recorded returns of +8.5% versus the Zacks S&P 500 composite's +1.9% change. Based on its Zacks Rank #2 (Buy), NBIX will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Neurocrine (NBIX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Wall Street analysts expect Neurocrine Biosciences (NBIX - Free Report) to post quarterly earnings of $2.26 per share in its upcoming report, which indicates a year-over-year increase of 113.2%. Revenues are expected to be $901.54 million, up 31.1% from the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Neurocrine metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Revenues- Product sales, net' will likely reach $881.08 million. The estimate indicates a year-over-year change of +29.2%.
Based on the collective assessment of analysts, 'Revenues- Collaboration revenue' should arrive at $6.02 million. The estimate points to a change of +9.4% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Product sales, net- INGREZZA' will reach $628.59 million. The estimate indicates a change of +0.7% from the prior-year quarter.
View all Key Company Metrics for Neurocrine here>>>Over the past month, Neurocrine shares have recorded returns of +8.5% versus the Zacks S&P 500 composite's +1.9% change. Based on its Zacks Rank #2 (Buy), NBIX will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .